We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+24.83%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$71.2M
Cap. Flow
+$5.62M
Cap. Flow %
1.56%
Top 10 Hldgs %
99.63%
Holding
13
New
–
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.21M
2
BMEA icon
Biomea Fusion
BMEA
+$2.41M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$262M 72.85%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$58.2M 16.18%
615,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$12.3M 3.43%
1,316,806
+291,806
+28% +$3.21M
GLUE icon
4
Monte Rosa Therapeutics
GLUE
$1.4B
$6.64M 1.85%
1,472,331
– –
BCAX
5
Bicara Therapeutics
BCAX
$1.78B
$5.29M 1.47%
568,919
– –
NUVB icon
6
Nuvation Bio
NUVB
$2.2B
$4.95M 1.38%
2,541,009
– –
BMEA icon
7
Biomea Fusion
BMEA
$84.6M
$3.69M 1.03%
2,048,757
+1,250,000
+156% +$2.41M
CMPS
8
Compass Pathways
CMPS
$1.53B
$3.36M 0.93%
1,198,418
– –
ELEV
9
DELISTED
Elevation Oncology
ELEV
$1.04M 0.29%
2,834,910
– –
CALC icon
10
CalciMedica
CALC
$15.8M
$834K 0.23%
521,114
– –
ACRS icon
11
Aclaris Therapeutics
ACRS
$726M
$617K 0.17%
434,455
– –
MRKR icon
12
Marker Therapeutics
MRKR
$18.8M
$498K 0.14%
325,370
– –
OKUR
13
OnKure Therapeutics
OKUR
$154M
$212K 0.06%
88,607
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Aisling Capital Management held 13 positions worth $360M, up 25% from $288M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Aisling Capital Management opened no new positions and made no exits, leaving the 13-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management added most to Syndax Pharmaceuticals in Q2 2025, an estimated $3.21M increase.
  • Aisling Capital Management's ten largest holdings make up 100% of its $360M portfolio in Q2 2025.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q2 2025.
  • Aisling Capital Management's portfolio value rose 25% quarter-over-quarter to $360M.

Based on Aisling Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.